Department of Thyroid and Breast Surgery, The Affiliated Huaian Hospital of Xuzhou Medical University, Huaian, China.
Department of General Surgery Center, The First Hospital of Jilin University, Changchun, China.
Diagn Cytopathol. 2023 Jul;51(7):441-448. doi: 10.1002/dc.25135. Epub 2023 Apr 12.
A preoperative method is desired to discriminate benign from malignant thyroid nodules. This retrospective study evaluated the diagnostic performance of BRAF (B-Raf proto-oncogene) mutation (BRAF ) positivity and fine-needle aspiration cytology (FNAC) relative to intraoperative frozen section pathology.
Patients underwent preoperative FNAC of thyroid nodules. Cytology specimens were classified according to the Bethesda System for Reporting Thyroid Cytopathology (BSRTC), and analyzed for BRAF using an amplification-refractory mutation system (ARMS). Thyroid tissue was surgically removed and frozen sections processed for histology. The sensitivities and specificities of each analysis were compared, alone and in combination.
Among 346 patients, 333/358 FNACs (93%) showed malignant nodules; 322 (93%) patients received a pathological diagnosis of papillary thyroid carcinoma (PTC). The sensitivity and specificity of BSRTC VI for malignancy was the highest among the BSRTC categories. Compared with FNAC, the BRAF analysis had significantly higher sensitivity and specificity. The diagnostic efficacy of frozen section pathology was significantly higher than that of either BSRTC category or BRAF analysis alone. Combining methods variably improved diagnostic performance. BRAF was not associated with capsule infiltration, neurovascular infiltration, mono- or multifocal PTC, lymph node metastasis, or clinical stage.
The diagnostic performance of preoperative BRAF determination was better than that of the BSRTC-FNAC category; combining both improved sensitivity and specificity. Patients with positive malignancy scores from both should be recommended for surgery; those with negative scores require close monitoring. Surgical treatment should include comprehensive intraoperative frozen section assessment. BRAF mutations cannot indicate aggressive treatment.
需要一种术前方法来区分甲状腺良恶性结节。本回顾性研究评估了 BRAF(B-Raf 原癌基因)突变(BRAF )阳性和细针穿刺细胞学(FNAC)与术中冰冻切片病理的诊断性能。
患者接受甲状腺结节的术前 FNAC。细胞学标本根据甲状腺细胞病理学报告的 Bethesda 系统(BSRTC)进行分类,并使用扩增不可阻挡突变系统(ARMS)分析 BRAF。切除甲状腺组织并进行冷冻切片处理以进行组织学检查。比较了每种分析单独和联合使用的敏感性和特异性。
在 346 例患者中,358 例 FNACs(93%)显示恶性结节;322 例(93%)患者接受了甲状腺乳头状癌(PTC)的病理诊断。BSRTC 分类中,BSRTC VI 对恶性肿瘤的敏感性和特异性最高。与 FNAC 相比,BRAF 分析具有更高的敏感性和特异性。冰冻切片病理的诊断效果明显高于 BSRTC 分类或 BRAF 分析单独的诊断效果。联合方法可不同程度地提高诊断性能。BRAF 与包膜浸润、神经血管浸润、单灶或多灶性 PTC、淋巴结转移或临床分期无关。
术前 BRAF 检测的诊断性能优于 BSRTC-FNAC 分类;两者结合可提高敏感性和特异性。两者均为恶性评分阳性的患者应推荐手术治疗;评分阴性的患者需要密切监测。手术治疗应包括全面的术中冰冻切片评估。BRAF 突变不能提示积极治疗。